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Abstract
The peculiarities of benign proliferative pathology of endometrium including their combination in women of reproductive age
are reviewed in the article.
Materials and methods. The results of pathohistological research of benign proliferative pathology of endometrium (without
atypia) were analyzed. Statistical data processing was performed by means of MedStat software package.
Results. The obtained results revealed that benign proliferative pathology of endometrium is one of the most frequent
gynaecological malignancies among female patients of reproductive age accounting for 52.2 % cases. Endometrial polyps
were found to be accompanied by morphological peculiarities indicating chronic inflammatory process in endometrium in
56.5% cases (p<0.05) in comparison with endometrial hyperplasia in 38.2% cases, proving the presence of long-term
inflammation in endometrial tissue and its trigger role in the development of the proliferative processes. Among patients
with chronic salpingo-oophoritis, infertility was revealed in almost half of cases (44.5% of patients with endometrial polyps,
40.5% of patients with endometrial hyperplasia and 48.3% of women with combined proliferative pathology of endometrium)
clinically confirming the data of morphological research. Peculiar signs of proliferative processes in genitals were determined,
namely coexistence of uterine and endometrial pathology: endometrial hyperplasia was found in 40.4% of patients with
uterine leiomyoma and 30.3% of patients with adenomyosis. The same combinations were peculiar for patients with
endometrial polyps: endometrial hyperplasia was found in 30.1% of patients with uterine leiomyoma and 36.3% of patients
with adenomyosis. Menstrual disorders were revealed in every third woman with endometrial hyperplasia (30.3%) and
co-existent polyposis (30.2%).
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Problem statement and analysis of the
recent research
Over the past decades there has been a significant increase in
the incidence of endometrial hyperplasia, cancer, and malig-
nant endometrial hyperplastic processes (EHP) [9].
The EHP group is represented by an aggregate of morpho-
logical and biological heterogenic changes in endometrium
varying from excessive proliferation to endometrial cancer
[11]. This group of diseases includes different variants of
hyperplasia and endometrial polyps.
Endometrial hyperplasia is a benign pathology of uterine
lining characterized by advanced clinicopathologic manifesta-
tions from simple to complex hyperplasia to atypical precursor
of endometrial cancer, which develops on the background of
absolute or relative hyperestrogenia [7]. Although estrogenic
stimulation of endometrium is considered the main etiological
risk factor for the development of endometrial hyperplasia,
some researchers indicated other factors, such as immunosup-
pression and infection [13].
Endometrial polyps are local benign proliferation of uter-
ine lining along with subjacent stroma [8].
A number of pathologists demonstrated that endometrial
polyps develop initially in focal basal hyperplasia of endometrium,
when nodes appear due to glandular and stromal hyperplasia
[12]; this explains a similarity of these different proliferative
nosologies.
Taking into consideration the diversity of histological con-
struction of different types of EHP, an issue of the unified
clinical interpretation of terminological definitions of the pro-
cess has long been the subject of constant discussions.
Thus, in 1943, the researchers Papanicolaou and Fraut re-
vealed that cytological investigation could diagnose endome-
trial cancer (they received a high percentage of coincidence
of vaginal smears and histological findings of endometrium in
patients with endometrial cancer); however, over the next 40
years the scientists had proven that the effectiveness of such
therapy was not more than 50%.
In 1994, the World Health Organization (WHO) adopted
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the classification of endometrial hyperplasia based on the
recommendations of leading gynaecologists, oncologists and
pathomorphologists, according to which the diagnostic crite-
rion for endometrial cancer precursors was the presence of
cytological atypia (endometrial hyperplasia without atypia –
simple or complex and atypical hyperplasia of endometrium
– simple or complex). The classification given above was
of great importance for the tactical selection of treatment,
whereas an important difference between these two kinds of
hyperplasia was the damage to tissue differentiation (complex
atypical hyperplasia, as compared to high-grade differentiated
adenocarcinoma, which has no signs of stromal invasion) [1].
However, the classification given above had some disad-
vantages – there were no established patterns of transforma-
tion of one kind of endometrial hyperplasia into another one or
endometrial cancer; concomitant sites of endometrial cancer
could remain unnoticed. This classification did not include a
separate classification of “endometrial polyp” considering the
recommendations how to interpret it in chronic endometritis
requiring the additional examination and adequate etiopatho-
genetic anti-inflammatory therapy, and hormonal therapy in
such cases was determined by the peculiarities of morpho-
functional structure of background endometrium [4, 10].
At the beginning of the 21st century (1999 and 2000), two
groups of morphologists: European Group of Experts and G.
Mutter with Endometrial Collaborative Group proposed to
reduce variants of endometrial hyperplasia from 4 to 2. Thus,
the European approach proposed endometrial hyperplasia and
endometrial neoplasia (EN), G. Mutter and co-authors pro-
posed endometrial hyperplasia and endometrial intraepithelial
neoplasia (EIN) [6].
Morphological differentiation of two categories consisted
in the visual analysis of architectonics of the parenchyma
(glands) and cytological changes and was confirmed by mor-
phometrically semi-quantitative determination of the ratio
between stroma and endometrial volume, considering the mea-
surements of stroma, epithelium and glandular lumen area
[17]. According to the calculations – EN/EIN is the prema-
lignant process with approximately 30% risk of malignant
changes requiring more thorough treatment and observation.
Some researches consider that such scheme predicts the rate
of disease progression more accurately than the classification
of 1994 [2, 18, 21].
The recent international guideline for the treatment of
endometrial hyperplasia adopted in 2016 by the Royal College
of Obstetricians and Gynaecologists (RCOG) and the British
Society of Gynaecological Endoscopy (BSGE), recommends
in practical activity to follow the 2014 WHO classification,
which divides endometrial hyperplasia into two groups based
on the presence of cytological atypia: hyperplasia without
atypia and atypical hyperplasia or hyperplasia with atypia
Class D [16].
Summarizing the above-mentioned information, it is nec-
essary to understand that despite the EHP classification chosen
by a doctor the important factor for differential diagnostics
between benign and malignant process is receiving a sufficient
quantity of the material which is possible only in diagnostic
curettage or endometrial aspiration [10].
According to normative and regulatory acts in the field
of medicine in Ukraine, namely – nomenclature coding, ap-
plication of international classification of diseases in the 10th
revision, we used the following classification during clinico-
pathologic research:
• N 84 Polyp of female genital tract.
• N 84.0 Polyp of corpus uteri.
• N 85 Other non-inflammatory uterus damages, except
cervix.
• N 85.0 Glandular hyperplasia of endometrium: poly-
cystic, glandular-polycystic polyp.
The objective of the research was to analyze morphological
data on abnormal endometrium in women of reproductive
age with gynaecological pathology to specify peculiarities
of pathogenetic mechanisms of reproductive health disorders
among a given population.
1. Materials and methods
There were analyzed 910 case reports of patients with be-
nign endometrial proliferative processes undergoing medical
treatment in the department of family planning and operative
rehabilitation of reproductive function in women of the Insti-
tute of Pediatrics, Obstetrics and Gynaecology of the National
Academy of Medical Sciences (NAMS) of Ukraine during
2010-2014.
Case reports were analyzed to determine the structure of
concomitant gynaecological pathology among a given popula-
tion.
Inclusion criteria were: the patient’s reproductive age
(18-49 years), the results of pathohistological research of be-
nign proliferative pathology of endometrium (without atypia):
endometrial polyp, endometrial hyperplasia, combined prolif-
erative endometrial pathology.
EHP was verified in all the patients at the preoperative
stage by ultrasound examination of the pelvic organs. Patients
were examined bacteriologically (the absence of sexually-
transmitted infections, as well as diagnostically significant
levels of bacterial load of non-specific opportunistic flora of
the reproductive tract was confirmed). In the preoperative
period, all patients received antibiotics, namely pluripotent
systemic preparations and local sanation.
To determine the state of the uterine cavity, to estimate the
localization of pathological changes in endometrium visually,
to control the quality of diagnostic curettage, hysteroscopy
was carried out in combination with further obligatory patho-
histologic investigation of the material received.
In concomitant gynaecological pathology requiring surgi-
cal treatment (tubo-peritoneal or combined forms of infertil-
ity), laparoscopy or laparotomy was performed.
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Laparoscopy and hysteroscopy with biopsy of endometrium
were performed by means of equipment manufactured by Aes-
culap and KarlStorz (Germany) according to standard proce-
dure.
Tissues received during surgery (uterine cavity curettage)
were used for histological analysis. The investigations were
carried out in pathomorphological laboratory of the Institute of
Pediatrics, Obstetrics and Gynaecology of NAMS of Ukraine.
Statistic data processing was carried out by means of
MedStat software package (Lyakh YuE, Guryanov VG, 2004-
2011). To represent quantitative signs - the median value
(Me) and the value of the first and third quartiles (QI – QIII)
[22] were calculated; to represent qualitative signs – the fre-
quency of manifestations (%) and the standard error (m%)
were calculated. To compare the indices in three groups,
the Kruskal-Wallis test was used, and as a post-hoc test the
Dunn’s multiple comparison test was used [22]. To compare
sign manifestation frequency, a chi-squared test was used [22];
the Marascuilo procedure was performed in post-hoc compar-
isons. In all cases, the results were statistically significant at
0.05.
2. Results and discussion
During 2010-2014, 1, 743 patients treated in the department
of family planning and operative rehabilitation of reproductive
function in women of the Institute of Pediatrics, Obstetrics
and Gynaecology of NAMS of Ukraine underwent surgery
(hysteroscopy, diagnostic curettage of the uterine cavity) due
to gynaecological diseases.
Among them, there were 910 (52.2%) patients of repro-
ductive age with benign proliferative pathology.
The distribution of cases (Fig. 1) is clearly indicative
of the absence of the decrease in the incidence of pathology
and rather stable indices within 5 years among the examined
women.
During the analysis of age structure of the examined fe-
male population, their age was found to vary from 18 to 49
years; the average age was 35 years.
According to Table 1, EHP was most frequently diagnosed
in women of reproductive age (71.0 %) - from 26 to 40 years
(in 26.2 %, they were at the age of 31-35 years).
According to the type of benign proliferative endome-
trial pathology, all the patients were distributed into 3 groups:
Group I included patients with endometrial polyps (n=705);
Group II comprised patients with verified endometrial hy-
perplasia (n=89); Group III included women with combined
endometrial pathology – hyperplasia and polyps (n=116).
Thus, the average age of women of Group I was 34 years
(from 24 to 48 years), the average age of women of Group
II was 35 years (from 25 to 46 years), the average age of
women of Group III was 36 years (from 25.3 years to 47
years), without statistically significant difference between the
research groups (p=0.81 in the Kruskal-Wallis test), allowing
us comparing data and analyze them.
The main pathohistological characteristics reflecting the
morphological state of the study material were the following:
signs of chronic endometritis, sites of fibromuscular tissue,
non-synchronous transformation of endometrium, stromal
fibrosis, hypoplasia of the mucous membrane (Fig. 2, Table
2).
Thus, according to Fig. 2, in all groups of patients, the
most frequent morphological sign was CIP in endometrium
(chronic endometritis and/or focal stromal fibrosis, develop-
ing on the background of long-lasting chronic inflammation,
sometimes involving rather large sites [5]), which was de-
tected in 56.5% of women with endometrial polyps, 38.2%
of patients with endometrial hyperplasia and 38.8% of pa-
tients with combined proliferative pathology of endometrium
(p<0.001). CIP was found more frequently in patients with
endometrial polyps than in those with endometrial hyperpla-
sia (p<0.05). There was no statistically significant difference
(p>0.05) when comparing groups with endometrial hyper-
plasia and combined proliferative pathology of endometrium.
The data mentioned above demonstrated the state of the
uterine cavity in patients with proliferative pathology of en-
dometrium without clinical signs of pelvic inflammatory dis-
ease since surgery and the presence of sexually transmitted
infections. Chronic endometritis was verified in more than
a half of patients with endometrial polyps and every third
woman with hyperplasia or combined proliferative pathology
of endometrium indicating the leading etiological role in the
pathology development - chronic subclinical inflammatory
process without an objective sign.
The data received coincided with modern microbiological
researches [14, 19], where a correlation between endome-
trial polyps and chronic endometritis developing on the back-
ground of high levels of bacterial contamination of reproduc-
tive tract (including Ureaplasma urealyticum or different as-
sociations of non-specific opportunistic flora) was determined
[20]. There is an idea that this may be one of the reasons
of excessive growth of endometrial tissue due to long-term
stimulation by biological inflammatory factors [14, 19].
It is necessary to note that in literature [15], there are only
few works describing the attempts to study endometrial polyps
of bacterial origin, necessitating more in-depth research of
bacterial and viral characteristics of biological environment
in patients with proliferative endometrial pathology.
The next morphological characteristics of the examined
material obtained from patients with proliferative endome-
trial pathology was the presence of fibromuscular tissue sites
(Table 2) which were found in 23.3% of patients with endome-
trial polyps, 18.0% of patients with endometrial hyperplasia
and 17.2% of females with combined endometrial prolifera-
tive pathology. The indices were rather uniform between the
groups without statistically significant difference (p=0.220).
The data described above indicated that approximately
every fifth woman of reproductive age suffering from endome-
trial proliferative pathology (polyps or signs of endometrial
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Figure 1. Frequency of EHP determination in patients who underwent surgery (hysteroscopy, diagnostic curettage of the
uterine cavity) during 2010-2014
Table 1. Distribution of the examined women per year, abs (%)
Index 18-25 26-30 31-35 36-40 41-45 46-49(years)
Abs. 56 201 238 207 140 68
(%) (6.1) (22.1) (26.2) (22.7) (15.4) (7.5)
Figure 2. Frequency of determination of chronic inflammatory process (CIP) of endometrium in patients with endometrial
proliferative pathology
hyperplasia according to ultrasound investigation) can have
uterine submucous myoma, which is rather difficult to visu-
ally differentiate from other EHP. Such a situation may be
a cause of unsuccessful results of conservative treatment of
such patients and the presence of more pronounced clinical
signs of the disease.
Endometrial tissue is known to be hormone-dependent
organ, functional activity of which depends completely on
Clinicopathologic Aspects of Endometrial Proliferous Processes in Women of Reproductive Age — 5/8
Table 2. Morphological characteristics of uterine cavity material in patients with proliferative pathology of endometrium, abs.
(%±m%)
Index
Manifestation frequency, abs. (%±m%)
pGroup I Group II Group III
(n=705) (n=89) (n=116)
Fibromuscular tissue sites
Yes 164 16 20
0.22(23.3±1.6) (18.0±4.1) (17.2±3.5)
No 541 73 96(76.7±1.6) (82.0±4.1) (82.8±3.5)
Non-synchronous transformation of endometrium
Yes 93 2 9
0.004(13.2±1.3)# (2.2±1.6)* (7.8±2.5)
No 612 87 107(86.8±1.3) (97.8±1.6) (92.2±2.5)
Hyperplasia of mucous membrane
Yes 23 3 –
0.14(3.3±0.7) (3.4±1.9)
No 682 86 116(96.7±0.7) (96.6±1.9) (100)
Notes.Chi-square analyses were used for comparison, post-hoc comparison was carried out with the application of the Marascuilo procedure.
* - the difference from Group I is statistically significant (p<0.05);
# - the difference from Group II is statistically significant (p<0.05).
steroid hormone homeostasis. Absolute or relative hyperestro-
genia causing disorders of cyclic function of endometrium
towards the proliferation and complications of tissue disor-
ders is proven to be the main pathogenetic component in the
formation of endometrial hyperplasia.
Non-synchronous endometrium transformation may oc-
cur secondary to it being histologically verified in patients
with proliferative pathology of endometrium in 13.2% to 2.2%
cases (13.2% - Group I, 2.2% - Group II, 7.8% - Group III).
There was a statistically significant difference (p=0.004) be-
tween patients with endometrial polyps and those with en-
dometrial hyperplasia expressing non-adequacy of homoge-
nous cyclic change in endometrial tissue in patients with en-
dometrial polyps.
The next stage of our research was the study of the struc-
ture of the reproductive system disease in patients with prolif-
erative endometrial pathology. It is reflected in Table 3.
We selected the most common nosological forms being
the main genital disorders in women of reproductive age (in-
fertility, chronic salpingitis, spike process of the pelvic organs,
uterine leiomyoma, adenomyosis), which were diagnosed at
patient’s discharge from the hospital.
Thus, in almost half of patients, infertility was detected
(44.5 % of patients with endometrial polyps, 40.5% of patients
with endometrial hyperplasia and 48.3% of women with com-
bined proliferative pathology of endometrium); there were
no statistically significant differences between the groups
(p=0.626). In Group I, 27.1% of patients had primary in-
fertility and 17.4% of patients had secondary infertility; in
Group II, primary infertility was found in 27.0% of cases and
secondary one was detected in 13.5% of women; in Group
III, primary infertility was diagnosed in 32.8% of patients,
secondary infertility was detected in 15.5% of patients.
The next nosological form of reproductive disorders was
CIP diagnosed in 50% of patients with endometrial polyps
and those with combined proliferative endometrial pathology
(50.1% and 50.0%, respectively). Lower index was observed
in women with endometrial hyperplasia – 44.9%, however, it
was too high (p=0.657).
Considering a high incidence of infertility and chronic
inflammatory process, the next stage was the analysis of the
tube-peritoneal factor indices – the presence of spike process
of the pelvic organs which was revealed in about every fourth
woman with the following distribution: Group I – in 28.7% of
patients, Group II – in 22.5% of patients, Group III – in 24.1%
of patients; there were no differences between the groups,
p=0.324.
Taking into account the priority direction of our work,
namely proliferative processes of endometrium, it was impor-
tant to estimate myometrial proliferative changes considering
the modern views on the unity and unidirectionality of these
pathological changes (“hyperplastic syndrome” [3]).
Thus, uterine leiomyoma was diagnosed in 30-40% of
women of reproductive age with endometrial proliferative
pathology: among women with endometrial polyps, leiomy-
oma was revealed in 30.1% of cases; among patients with hy-
perplasia of endometrium, it was found in 40.4% of cases; pa-
tients with combined proliferative pathology of endometrium
were diagnosed with leiomyoma in 29.3% of cases; there were
no differences between the groups, p=0.125.
Adenomyosis was diagnosed in 30-38% of patients with
proliferative endometrial pathology: among patients of Group
I, adenomyosis was diagnosed in 36.3% of cases; among
patients of Group II, it was observed in 30.3% of cases; 37.9%
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Table 3. Structure of reproductive system diseases in patients with endometrial proliferative pathology abs. (%±m%)
Index
Manifestation frequency, abs. (%±m%)
pGroup I Group II Group III
(n=705) (n=89) n=116)
Infertility
I1 191 24 38
0.63
(27.1±1.7) (27.0±4.7) (32.8±4.4)
I2 123 12 18(17.4±1.4) (13.5±3.6) (15.5±3.4)
No 391 53 60(55.5±1.9) (59.5±5,2) (51.7±4.6)
Chronic salpingitis
Yes 353 40 58
0.66(50.1±1.9) (44.9±5.3) (50.0±4.6)
No 352 49 58(48.9±1.9) (55.1±5.3) (50.0±4.6)
Spike process of the pelvic organs
Yes 202 20 28
0.32(28.7±1.7) (22.5±4.4) (24.1±4.0)
No 503 69 88(71.3±1.7) (77.5±4.4) (75.9±4.0)
Uterine leiomyoma
Yes 212 36 34
0.13(30.1±1.7) (40.4±5.2) (29.3±4.2)
No 493 53 82(69.9±1.7) (59.6±5.2) (70.0±4.2)
Adenomyosis
Yes 256 27 44
0.48(36.3±1.8) (30.3±4.9) (37.9±4.5)
No 449 62 72(63.7±1.8) (69.7±4.9) (62.1±4.5)
Note. Chi-square analyses were used for comparison.
patients of Group III group were diagnosed with adenomyosis;
there were no differences between the groups, p=0.483), i.e.,
in evry third woman, proliferative endometrial processes co-
existed with adenomyosis.
Considering the unity of proliferate cascade of reactions in
those patients, the state of ovarian tissue was examined, allow-
ing us to determine the presence of functional ovarian cysts
(OC) (endometrioid cyst (EC), corpus luteum cyst (CLC), fol-
licular cyst (FC)) and parovarian ganglions (PG) (Morgagni’s
cysts, parovarian cysts) in insignificant number of women
(Table 4).
Thus, in patients with endometrial polyps, this index was
as follows: EC was seen in 5.4% of cases, CLC was revealed
in 0.6% of women, FC was found in 0.4% of patients, PG
were revealed in 2.7% of females. In women with endometrial
hyperplasia, there was the following distribution: EC was seen
in 2.2% of cases, CLC was revealed in 1.1% of women, FC
was found in 5.6% of patients, PG were diagnosed in 4.5% of
females. In combined proliferative endometrial pathology, EC
was seen in 7.0% of patients, CLC was revealed in 0.9% of
women, FC was found in 1.7% of patients, PG was diagnosed
in 2.6% of women. The only difference between the groups
concerned ovarian follicular cyst being statistically significant
at a level <0.001 with index increase from 0.4% in patients
with local endometrial pathology up to 5.6% in women with
endometrial hyperplasia.
Polycystic ovarian syndrome was determined with equal
frequency in patients of Group II and Group III (12.4% and
12.9%, respectively), with a tendency to decrease in women
with endometrial polyps – up to 6.7% of cases.
The patient’s complaint of menstrual disorders is known
to be the most frequent clinical manifestation of endome-
trial hyperplasia. It developed in 30.3% to 18.4% of patients
(30.3% of patients with endometrial hyperplasia, 30.2% of
patients with combined proliferative endometrium pathology,
18.4% of women with endometrial polyps), with a difference
(p=0.001) between patients with endometrial polyps and pa-
tients of two other groups - it may be used as a convenient
diagnostic marker.
3. Conclusions
1. Benign proliferative pathology of endometrium is one
of the most frequent gynaecological malignancies among
female patients of reproductive age who underwent hos-
pital treatment accounting for 52.2 % cases.
2. Endometrial polyps were found to be accompanied
by morphological peculiarities indicating CIP in en-
dometrium in 56.5% cases (p<0.05) in comparison
with endometrial hyperplasia in 38.2% cases, proving
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Table 4. State of the ovaries in patients with endometrial proliferative pathology, abs. (%±m%)
Index
Manifestation frequency, abs. (%±m%)
pGroup I Group II Group III
(n=705) (n=89) (n=116)
OC
Yes 19 4 3
0.62(2.7±0.6) (4.5±2.2) (2.6±1.5)
No 686 85 113(97.3±0.6) (95.5±2.2) (97.4±1.5)
EC
Yes 38 2 8
0.32(5.4±0.9) (2.2±1.6) (7.0±2.4)
No 667 87 108(94.6±0.9) (97.8±1.6) (93.0±2.4)
CLC
Yes 4 1 1
0.80(0.6±0.3) (1.1±1.1) (0.9±0.9)
No 701 88 115(99.4±0.3) (98.9±1.1) (99.1±0.9)
FC
Yes 3 5 2
<0.001(0.4±0.2)# (5.6±2.4)* (1.7±1.2)
No 702 84 113(99.6±0.2) (94.4±2.4) (98.3±1.2)
Polycystic ovarian syndrome
Yes 47 11 15
0.02(6.7±0.9) (12.4±3.5) (12.9±3.1)
No 658 78 101(93.3±0.9) (87.6±3.5) (87.1±3.1)
Menstrual disorders
Yes 130 27 35
0.001(18.4±1.5)$ (30.3±4.9) (30.2±4.3)*
No 575 62 81(81.6±1.5) (69.7±4.9) (69.8±4.3)
Notes. Chi-square analyses were used for comparison, post-hoc comparison was carried out with the application of the Marascuilo procedure
* – the difference from Group I is statistically significant (p<0.05);
# – the difference from Group II is statistically significant (p<0.05);
$ – the difference from Group III is statistically significant (p<0.05).
the presence of long-term inflammation in endometrial
tissue and its trigger role in the development of the
proliferative processes.
3. Among patients with chronic salpingo-oophoritis, in-
fertility was revealed in almost half of cases (44.5%
of patients with endometrial polyps, 40.5% of patients
with endometrial hyperplasia and 48.3% of women with
combined proliferative pathology of endometrium) clin-
ically confirming the data of morphological research.
4. Characteristic features of genital proliferative processes
were determined, namely coexistence of uterine and
endometrial pathology: endometrial hyperplasia was
found in 40.4% of patients with uterine leiomyoma and
30.3% of patients with adenomyosis. The same com-
binations were peculiar for patients with endometrial
polyps: endometrial hyperplasia was found in 30.1% of
patients with uterine leiomyoma and 36.3% of patients
with adenomyosis
5. The state of menstrual function in patients with prolif-
erative pathology of endometrium was characterized by
cycle disorders in every third woman with endometrial
hyperplasia (30.3%) and co-existent polyposis (30.2%),
which proves the advisability of mandatory ultrasound
investigation which allows diagnosing endometrial pro-
liferative process in a patient at the outpatient stage.
6. The given above data indicate that the issue considered
is one of the main problems in modern gynaecology
as well as reproductive medicine and should be patho-
genetically substantiated and solved in an integrated
manner.
References
[1] Zaporozhan VM. Obstetrics and gynecology. Zaporozhan
VM, editor. Neoperatyvna hinekolohiya. 2014; 502-503.
[2] Bishtavi AH, Manuhin IB, Tabakman YY. Modern con-
cepts of endometrial hyperplasia and endometrial intraep-
Clinicopathologic Aspects of Endometrial Proliferous Processes in Women of Reproductive Age — 8/8
ithelial neoplasia (literature review). Problemy reprodukt-
sii. 2010; 6: 52-8.
[3] Vishnevskyi AS. Hyperplastic syndrome in gynaecology.
InformMed. c2013; 188p.
[4] Kovalenko EP, Tatarchuk TF, Kubyshkin AV, Filonenko
TG. Endometrial hyperplasia and inflammation: evalua-
tion of leukocyte infiltration and level of proinflammatory
cytokines. Zdorovye zhenshchiny. 2011; 7 (63): 142-145.
[5] Kuznetsova AV. Chronic endometritis. Arh. patol. 2000;
3 (62): 48-52.
[6] Metelskaya MA, Rogov YI. The possibilities of using a
computer image analyzer for differential diagnosis of en-
dometrial hyperplastic processes. Onkologicheskiy zhur-
nal. 2012; 3 (23): 15-22.
[7] On approval of clinical protocols for obstetric and gyneco-
logical care. The Order of Ministry of Health of Ukraine
of 03.11.2008 No 624.
[8] Vihlyaeva EM, Zheleznov BI. Polyps of the endometrium.
Guide to Endocrine Gynecology. 3rd ed. 2006; 447-462.
[9] Zaporozhan VN, Tatarchuk TF. Modern diagnostics and
treatment of endometrial hyperplastic processes. Repro-
duktivnaya endokrinologiya. 2012; 1 (3): 5-12.
[10] Tatarchuk TF, Zadorozhna TD, Vorobyova LI. Modern
principles of diagnosis and treatment of hyperplastic
processes of endometrium. Metodychni rekomendatsiyi.
Kyiv; 2005.
[11] Chernuha GE. Hyperplasia of the endometrium: the
prospects for the development of the problem. Akush-
erstvo i ginekologiya. 2009; 4: 11-14.
[12] Yakovleva IY, Kukuteh VG. Morphological diagnosis of
precancerous processes and uterine tumors by biopsy and
scrapings. 1979; 145.
[13] Bobrowska K, Kamin´ski P, Cyganek A, Pietrzak B,
Jabiry-Zieniewicz Z, Durlik M. High rate of endometrial
hyperplasia in renal transplanted women. Transplantation
Proceedings. 2006; 178-197.
[14] El-Hamarneh T, Hey-Cunningham AJ, Berbic M, Al-
Jefout M, Fraser IS, Black K. Cellular immune environ-
ment in endometrial polyps. Fertil Steril. 2013; 100 (5):
1364-1372. DOI: https://doi.org/10.1016/j.
fertnstert.2013.06.050 [PMid:23931965]
[15] Kitaya K, Yasuo T. Aberrant expression of selectin E,
CXCL1, and CXCL13 in chronic endometritis. Modern
Pathology. 2010; 23 (8): 1136-1146. DOI: https://
doi.org/10.1038/modpathol.2010.98
[16] Green-top Guideline 67 RCOG/BSGE Joint Guideline of
February 2016. Management of Endometrial Hyperplasia.
[17] Mutter GL. Endometrial intraepithelial neoplasia (EIN):
will it bring order to chaos? The Endometrial Collab-
orative Group. Gynecol Oncol. 2000; 76 (3): 287-290.
DOI: https://doi.org/10.1006/gyno.1999.
5580
[18] Mutter GL, Baak JPA, Crum CP, Richart RM,
Ferenczy A, Faquin WC. Endometrial precancer
diagnosis by histopathology, clonal analysis, and
computerized morphometry. J Pathol. 2000; 190 (4):
462-469. DOI: https://doi.org/10.1002/
(SICI)1096-9896(200003)190:4<462::
AID-PATH590>3.0.CO;2-D
[19] Al-Jefout M, Black K, Schulke L, Berbic M, Luscombe
G, Tokushige N et al. Novel finding of high density of
activated mast cells in endometrial polyps. Fertil Steril.
2009; 92 (3): 1104-1106. DOI: https://doi.org/
10.1016/j.fertnstert.2009.02.016
[20] Cicinelli E, De Ziegler D, Nicoletti R, Tinelli R, Saliani
N, Resta L, et al. Poor reliability of vaginal and en-
docervical cultures for evaluating microbiology of en-
dometrial cavity in women with chronic endometritis.
Gynecol Obstet Invest. 2009; 68 (2): 108-115. DOI:
https://doi.org/10.1159/000223819
[21] Skov BG, Broholm H, Engel U, Franzmann MB, Nielsen
AL, Lauritzen AF, et al. Comparison of the reproducibil-
ity of the WHO classifications of 1975 and 1994 of
endometrial hyperplasia. Int J Gynecol Pathol. 1997;
16 (1): 33-37. DOI: https://doi.org/10.1097/
00004347-199701000-00006 [PMid:8986530]
[22] Petrie A, Sabin C. Medical Statistics at a Glance. 2nd ed.
c2005. 157p.
Received: 14 Nov 2017
Revised: 26 Dec 2017
Accepted: 26 Dec 2017
